secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2023-03-13T23:59:59+00:00
Accession:  0000950170-23-007578
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences Q4 2022 revenue up 40% YoY to $20.5M; guides 2023 revenue $89-94M
--------------------------------------------------------------------------------

- Full-year 2022 revenue $71.3M (+46% YoY); Surgical Glaucoma $65.6M (+41%), Dry Eye $5.7M (+133%).
- Q4 2022 net loss $16.9M ($0.35/share) vs $15.9M loss ($0.34/share) in Q4 2021.
- Q4 2022 operating expenses $33.9M, down 10% sequentially from Q3 2022.
- OMNI facilities reached 941 and TearCare facilities grew to 1,042 as of Dec 31, 2022.
- 2023 revenue guidance $89M-$94M, representing 25%-32% growth over 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000095017023007578/0000950170-23-007578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000095017023007578/sght-20230313.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer